Evidence map›Paper›PMID 42571987›Full record

ArticleJournal of extracellular vesicles2026

Shear-Activated von Willebrand Factor Captures Extracellular Vesicles to Promote Platelet Activation and Metastasis.

Yuanyuan Wang, Xiaobo Liu, Pascal Nakielski, Katrin Nekipelov, Amanda Salviano-Silva, Alper Topuz, Alexander T Bauer, Julian Kött, Jannis Akrivakis, Santra Brenna and 7 more

Abstract read
In one paragraph

Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yuanyuan WangDepartment of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Xiaobo LiuDepartment of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pascal NakielskiCenter for Hybrid Nanostructures (CHyN), Universität Hamburg, Hamburg, Germany.
Katrin NekipelovPharmaceutical Institute, University of Bonn, Bonn, Germany.
Amanda Salviano-SilvaDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Alper TopuzInstitute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany.
Alexander T BauerDepartment of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Julian KöttDepartment of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jannis AkrivakisDepartment of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Santra BrennaNeurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tomasz DownarExperimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Neus FeliuCenter for Hybrid Nanostructures (CHyN), Universität Hamburg, Hamburg, Germany.
Gerd BendasPharmaceutical Institute, University of Bonn, Bonn, Germany.
Berta PuigNeurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-2255-8393
Stefan W SchneiderDepartment of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dmitry A FedosovInstitute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany.
Christian GorzelannyDepartment of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-3788-6429

Funding

Deutsche Forschungsgemeinschaft CRC1700Deutsche Forschungsgemeinschaft GO 2528/10-1Deutsche Forschungsgemeinschaft GRK 2873Hamburg Pro Exzellenzia PlusMildred Scheel Cancer Career Center HaTriCS4
6 · The paper itself

Abstract

Plasma proteins are increasingly recognized as key regulators of extracellular vesicle (EV) behaviour in circulation. However, von Willebrand factor (vWF)-the largest multimeric glycoprotein in blood and the only blood protein activated by shear-has received little attention in this context. Under elevated shear stress, vWF transitions from a compact globular form to an extended adhesive conformation. Although elevated plasma vWF levels are associated with hypercoagulation in conditions such as malaria, COVID-19, and cancer, its interactions with EVs or cells under physiological flow have not been systematically investigated. Here, we show that shear-activated vWF functions as a size-selective molecular filter that preferentially captures objects smaller than ∼4 µm, including platelets and tumour-derived EVs, while excluding larger cells. Although intact tumour cells do not directly bind vWF under physiological flow, the coordinated binding of EVs and platelets to extended vWF promotes platelet aggregation, which subsequently traps circulating tumour cells and fosters metastatic dissemination. Our findings reveal a previously unrecognized role of vWF as a shear-dependent EV-binding protein that brings EVs and platelets together to enhance coagulation and metastasis. These EV-vWF-platelet aggregates may represent promising biomarkers or therapeutic targets for the prevention of hypercoagulation in cancer and other thrombo-inflammatory diseases.

Indexed as

Extracellular VesiclesPlatelet Activationvon Willebrand FactorAnimalsBlood PlateletsCell Line, TumorHumansNeoplasm MetastasisPlatelet Aggregationvon Willebrand Factorblood flowcirculating tumour cellheparan sulfatemelanomaplasma proteinthrombosistissue factor

Identifiers

PMID42571987
PMCPMC13453939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.